Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2-phenylpyridine derivative

A technology of phenylpyridine and derivatives, applied in the field of 2-phenylpyridine derivatives, can solve the problems of the inhibition of xanthine oxidase and the inhibition of uric acid synthesis, which is not disclosed or implied, and achieves strong inhibition of xanthine oxidase. Effect

Inactive Publication Date: 2007-08-01
ASTELLAS PHARMA INC
View PDF10 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] However, in Patent Document 10 and Non-Patent Document 2, neither the inhibitory effect on xanthine oxidase nor the inhibitory effect on uric acid synthesis is disclosed nor suggested.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-phenylpyridine derivative
  • 2-phenylpyridine derivative
  • 2-phenylpyridine derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0199] Hereinafter, the production method of the compound (I) of the present invention will be described in more detail based on examples. However, the present invention is not limited to the compounds described in the following Examples. In addition, the manufacturing method of a raw material compound is shown in a reference example.

[0200] In addition, the following abbreviations are used in the reference example, an Example, and the table|surface mentioned later.

[0201] Ex: Example number, REx: Reference example number, Dat: Physicochemical data (F: FAB-MS (M+H) + , FN: FAB-MS (M-H) - 、ES:ESI-MS(M+H) + , EI: EI-MS(M) + 、APN: API-ES-MS(M-H) - , [The compound described as (Na) after the above-mentioned mass spectrometry measurement value indicates that it was observed as a Na salt, and the compound described as (G-2W) indicates that it was observed as a glycerol adduct dianhydrate ], NMR: DMSO-d 6 middle 1 δ (ppm) of the characteristic peak in H NMR, NMRC: CDCl 3...

reference example 1

[0203] Heating 5-bromo-2-hydroxybenzonitrile, isobutyl bromide and potassium carbonate in DMF at 80 °C in the presence of tetra-n-butylammonium bromide gives 5-bromo-2-isobutoxybenzonitrile . F: 254, 256

reference example 2

[0205] After stirring 2,2-dimethyl-1-propanol and sodium hydride in DMF at 0°C, 5-bromo-2-fluorobenzonitrile was added to react at room temperature to give 5-bromo-2-(2,2 -dimethylpropoxy)benzonitrile. NMRC: 3.67 (2H, s), 6.83 (1H, d), 7.64 (1H, d)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a 2-phenylpyridine derivative or a salt thereof of formula (I). This compound has satisfying xanthine oxidase-inhibitory action and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like. The following are the sign meanings of formula (I): R<1>: H, etc; R<2>: -CO<2>H, etc; R<3> and R<4>:H, etc; R<5>: -CN, etc; R<6>: H, etc; X: -O- and -N(R<8>)- or -S-(under condition that bases indicated by R<5> and -X-R<7> combine at intervals or counterpoints compared with pyridyl); R8: H, etc; R<7>: C<1 to 8> direct or chain alkyl, etc; Y: key, etc; R<9>, R<10> and R<11>:H, etc (condition: when X equals -N(R<8>)-, R<8> and R<7> can have key merger and form nitrogen saturation heterocyclic together the adjacent nitrogen atoms.

Description

technical field [0001] The present invention relates to 2-phenylene as a medicine, especially as a medicine for treating or preventing diseases involving xanthine oxidase such as hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy, and diabetic retinopathy. Pyridine derivatives. Background technique [0002] The abnormal increase of uric acid value in the blood, i.e. hyperuricemia, is a disease closely related to gout, renal dysfunction, urolithiasis, etc. (Diagnosis and Treatment, 2002, 90 (2), 244-248; Diagnosis and Treatment, 2002, 90(2), 220-224). In addition, it is known that in organ transplantation (Ren. Fail. 2002 May; 24(3): 361-7) and cancer chemotherapy (Am. J. Health Syst. Pharm. 2003 Nov 1; 60(21): 2213-22), the serum uric acid value also increased significantly, causing renal dysfunction (tumor lysis syndrome). Drugs for the treatment of hyperuricemia are roughly divided into uric acid excretion promoters and uric acid synthesis inhibitors,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D213/79A61K31/541A61P1/04A61P3/10A61P9/04A61P9/10A61P13/12A61P19/06A61P29/00A61P35/00A61P43/00C07D401/04C07D401/10C07D401/12C07D405/12C07D413/10C07D417/10A61K31/4418A61K31/4439A61K31/444
Inventor 宫田淳司内藤良川上政胜浅野亨
Owner ASTELLAS PHARMA INC
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More